GeoVax Labs, Inc. filed a Form 8-K on November 9, 2026, disclosing the appointment of Shahin Behroyan as a director effective November 5, 2026, and the appointment of Tyler O'Brien as interim Chief Executive Officer and Chairman of the Board effective November 8, 2026.

Key Highlights

  • New Director: Shahin Behroyan was appointed to the GeoVax Labs Board of Directors effective November 5, 2026, filling a vacancy created by the resignation of five former directors on October 23, 2026.
  • Independence Determination: The Board determined that Mr. Behroyan is independent under Nasdaq Listing Rule 5605(a)(2) and satisfies the independence requirements of Rule 10A-3 under the Exchange Act.
  • Current Role Elsewhere: Mr. Behroyan has served as chief executive officer of iSpecimen, Inc. (Nasdaq: ISPC) since August 26, 2026.
  • Interim CEO Appointed: Tyler O'Brien was appointed interim Chief Executive Officer effective November 8, 2026, to perform the functions of principal executive officer until a permanent appointment is made.
  • Chairman Designation: Tyler O'Brien was also appointed Chairman of the Board effective November 8, 2026.
  • Standard Compensation: Mr. Behroyan will receive the standard compensation available to the company's current non-employee directors, according to the filing.

GeoVax Board Restructuring: Behroyan and O'Brien Step Into New Roles

According to the filing, GeoVax Labs, Inc. (NASDAQ:GOVX) reported two significant leadership changes in the same 8-K. The appointment of Shahin Behroyan fills a vacancy that arose after five former directors resigned simultaneously on October 23, 2026. The Board appointed Mr. Behroyan directly, by the affirmative vote of a majority of the directors then in office. The filing states Mr. Behroyan has not been immediately appointed to any committee of the Board of Directors.

The filing describes Mr. Behroyan, age 39, as "a Vancouver-based entrepreneur and business leader with more than two decades of experience spanning investments, consumer packaged goods, healthcare and wellness, politics, and market research." According to the filing, he holds a Bachelor of Arts from Simon Fraser University and has extensive experience in political organizing, including work for former British Columbia Premier Gordon Campbell, as well as market research expertise from his work with Campaign Research of Toronto. The Board stated it believes his "experience in corporate transactions, strategic acquisitions and complex financing agreements qualifies him to serve as a director."

Separately, the filing disclosed that Tyler O'Brien was appointed interim Chief Executive Officer and Chairman of the Board, both effective November 8, 2026. The filing states that Mr. O'Brien will perform the functions of principal executive officer, including certifications required under Rules 13a-14 and 15d-14 of the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, until a permanent principal executive officer is appointed or designated. The filing was signed by Mark W. Reynolds, Chief Financial Officer, on November 9, 2026.

What Was Disclosed

GeoVax Labs disclosed the appointment of Shahin Behroyan as an independent director effective November 5, 2026, and Tyler O'Brien as interim Chief Executive Officer and Chairman of the Board effective November 8, 2026, following the departure of five directors in October 2026.